O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko
{"title":"Optimal dosage regimen of Ranquilon® for patients with anxiety associated with neurasthenia and adaptation disorders: phase II clinical trial","authors":"O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko","doi":"10.32756/0869-5490-2023-4-36-40","DOIUrl":null,"url":null,"abstract":"To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2023-4-36-40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
